Pliant Therapeutics: Strange Volatility

2025-02-11 00:31:37 ET

Summary

• Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations, causing significant stock volatility.
• High trading volumes and sharp stock declines occurred before the announcement, indicating potential insider activity, making PLRX highly risky for retail investors.
• The DSMB's rationale for pausing the trial remains unclear, with no major safety issues previously reported, adding to the uncertainty.
• PLRX has a cash runway of 5–6 quarters, but faces risks due to volatile stock movements and confusing trial data; I recommend avoiding PLRX.

Note the following timeline:

On Feb. 07, 2025 at 4:58 PM ET, Pliant Therapeutics ( PLRX ) made a major announcement —the company was voluntarily pausing the phase 2b/3 trial of bexotegrast in patients with Idiopathic Pulmonary Fibrosis. You can see the exact time in the press release below....

Read the full article on Seeking Alpha

For further details see: